List of Excipients in Branded Drug AZILECT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aphena Pharma Solutions - Tennessee LLC	AZILECT	rasagiline mesylate	43353-015	MANNITOL
Aphena Pharma Solutions - Tennessee LLC	AZILECT	rasagiline mesylate	43353-015	SILICON DIOXIDE
Aphena Pharma Solutions - Tennessee LLC	AZILECT	rasagiline mesylate	43353-015	STARCH, CORN
Aphena Pharma Solutions - Tennessee LLC	AZILECT	rasagiline mesylate	43353-015	STEARIC ACID
Aphena Pharma Solutions - Tennessee LLC	AZILECT	rasagiline mesylate	43353-015	TALC
Physicians Total Care Inc	AZILECT	rasagiline mesylate	54868-6206	MANNITOL
Physicians Total Care Inc	AZILECT	rasagiline mesylate	54868-6206	SILICON DIOXIDE

Azilect Excipient Strategy and Commercial Opportunities for Rasagiline Tablets

Last updated: August 2, 2026

Azilect is an immediate-release rasagiline mesylate tablet with a relatively simple excipient profile and limited formulation complexity. The principal commercial opportunity is not a conventional generic tablet, where competition is established, but differentiated delivery systems, fixed-dose combinations, regional manufacturing, excipient substitution, and lifecycle products that improve adherence or administration.

What is Azilect and which excipients does it contain?

Azilect contains rasagiline mesylate, a selective monoamine oxidase-B inhibitor approved for Parkinson's disease. The U.S. product is supplied as 0.5 mg and 1 mg oral tablets. The reference product is an immediate-release, nonmodified-release dosage form.[1]

Publicly reported inactive ingredients for Azilect include:

Excipient	Likely formulation function
Mannitol	Diluent, bulking agent, mouthfeel modifier
Starch or pregelatinized starch	Binder and disintegrant
Talc	Glidant and anti-adherent
Colloidal silicon dioxide	Glidant and flow aid
Stearic acid	Lubricant

The exact excipient declaration should be verified against the applicable FDA label and current DailyMed record before regulatory or manufacturing use. Excipient composition can differ between the reference product, authorized generics, and ANDA products.[1,2]

The formulation is commercially important because it does not depend on a complex delivery platform. A conventional rasagiline tablet can generally be developed using standard blending, granulation or direct compression, lubrication, coating, and packaging operations.

What formulation characteristics create commercial opportunities for rasagiline?

The principal formulation opportunity is to improve patient usability without changing the established pharmacological profile.

Immediate-release tablet opportunity

The existing dosage form creates a low technical barrier for generic entry. A competing product can use different inactive ingredients if it demonstrates pharmaceutical equivalence, bioequivalence, stability, and appropriate quality controls.

Potential excipient strategies include:

• Direct-compression formulations using mannitol, microcrystalline cellulose, and low-level superdisintegrants.
• Wet-granulated tablets for improved content uniformity at the 0.5 mg strength.
• Low-moisture formulations to protect chemical stability.
• Film-coated tablets using standard hypromellose-based coating systems.
• Smaller tablets for patients with swallowing difficulty.
• Color and imprint differentiation to reduce medication errors.
• Unit-dose blister packaging for adherence and dispensing control.

The low dose of rasagiline creates a content-uniformity issue that can be more important than tablet size. A 0.5 mg tablet contains a small amount of active pharmaceutical ingredient relative to the excipient mass. Blend homogeneity, segregation control, sampling design, and assay variability therefore require close attention.

Orally disintegrating tablet opportunity

An orally disintegrating tablet, or ODT, is a potential lifecycle product for Parkinson's patients who have dysphagia, impaired dexterity, or difficulty taking conventional tablets.

A typical ODT strategy could use:

• Mannitol for rapid dissolution and cooling mouthfeel.
• Crospovidone, croscarmellose sodium, or sodium starch glycolate for disintegration.
• Low-level silicon dioxide to improve powder flow.
• Taste-masking agents or polymeric coatings if rasagiline produces unacceptable bitterness.
• Direct compression or freeze-drying, depending on target performance and cost.

The regulatory value of an ODT depends on whether the product is submitted as a new drug, a reformulation, or another pathway. A new dosage form may require clinical bridging, comparative pharmacokinetics, and evidence that the product does not alter exposure in a clinically meaningful way. An ODT may obtain separate patent protection for composition, manufacturing, or performance characteristics, but the excipient combination alone is not automatically patentable.

Oral film and multiparticulate opportunities

Oral films could target patients who cannot reliably swallow tablets. The main technical issues are low-dose uniformity, film mass, mechanical strength, moisture sensitivity, taste, and rasagiline distribution across the film matrix.

Multiparticulate products, including orally administered granules or mini-tablets, could offer flexible dosing. Their commercial value would be higher if combined with a clinically useful feature, such as easier titration or administration through feeding systems. Without such differentiation, the product would compete with low-cost generic tablets.

What excipient patents could protect a rasagiline product?

Excipient protection is usually indirect. A patent applicant generally needs to claim a specific composition, process, dosage form, or performance result rather than merely identify a familiar pharmaceutical excipient.

Potential claim categories include:

Claim category	Potential commercial purpose
Specific excipient ratio	Protects a composition with defined manufacturability or dissolution
Low-dose content-uniformity process	Protects blending, granulation, or segregation controls
Taste-masked rasagiline composition	Protects a patient-friendly oral dosage form
ODT composition	Protects rapid disintegration and acceptable mouthfeel
Moisture-protective formulation	Protects stability under defined storage conditions
Fixed-dose combination	Protects coadministration with another Parkinson's therapy
Manufacturing process	Protects scale-up, yield, polymorph control, or impurity reduction
Packaging system	Protects moisture or light protection where tied to product stability

A patent directed only to mannitol, starch, talc, or a standard lubricant would generally face substantial novelty and obviousness challenges. Stronger protection would require a defined technical effect, such as improved content uniformity, reduced degradation, rapid disintegration, or a clinically relevant administration advantage.

How does the Azilect formulation compare with competing Parkinson's drugs?

Rasagiline competes with other Parkinson's treatments that use different dosage-form and excipient strategies.

Product or class	Active ingredient	Common dosage-form profile	Excipient opportunity
Azilect	Rasagiline mesylate	Immediate-release tablet	ODT, oral film, fixed-dose combinations
Selegiline tablets	Selegiline hydrochloride	Oral tablet	ODT and taste-masked products
Zelapar	Selegiline hydrochloride	Orally disintegrating tablet	Benchmark for adherence-focused delivery
Safinamide	Safinamide mesylate	Immediate-release tablet	Combination therapy and adherence packaging
Levodopa/carbidopa	Levodopa and carbidopa	Immediate-release and extended-release products	Modified release, intestinal delivery, combination products
Rotigotine	Rotigotine	Transdermal patch	Alternative delivery rather than excipient competition

Zelapar demonstrates that an MAO-B inhibitor can be positioned in an orally disintegrating dosage form. That precedent may reduce market education costs for a rasagiline ODT, although it does not eliminate technical or regulatory requirements.[3]

The strongest commercial distinction for rasagiline would likely be administration convenience, not a new pharmacodynamic claim. A product that reduces swallowing burden or improves adherence may have more defensible value than a tablet using a different conventional filler.

When did Azilect lose exclusivity and what is the generic status?

Azilect was approved by the FDA in 2006. The product received the standard new chemical entity exclusivity period associated with its original approval, subject to the specific approved indications and regulatory record.[1,4]

The core U.S. composition and use patents associated with rasagiline have expired or are no longer the principal commercial barrier to conventional generic entry. FDA records show approved generic rasagiline products, making the immediate-release tablet market an established generic segment.[4,5]

Milestone	Status
FDA approval of Azilect	2006
Original reference product	Teva Pharmaceuticals, with development history involving Lundbeck
Strengths	0.5 mg and 1 mg tablets
Dosage form	Immediate-release oral tablet
NCE exclusivity	Expired
Conventional generic entry	Established
Current strategic barrier	Differentiation, manufacturing economics, regulatory execution, and lifecycle IP

The exact Orange Book patent listings and expiration dates should be assessed by product and listing status because patents can be delisted, expire, or cease to constrain ANDA approval. A standard rasagiline tablet should not be valued on the assumption that legacy Azilect exclusivity remains a significant barrier.

What is the Orange Book status of Azilect?

The Orange Book identifies reference-listed drugs, approved generic equivalents, patent listings, and exclusivity information. For Azilect, the relevant regulatory question is whether any active listed patent or exclusivity remains capable of delaying approval of a new ANDA.[4]

A generic applicant must address listed patents through certification under section viii, Paragraph IV, or another applicable pathway. Method-of-use patents can remain relevant even after composition patents expire if the proposed label includes a patented indication or dosing method.

For a conventional rasagiline product, the main regulatory risks are:

1. Failure to demonstrate bioequivalence at both strengths.
2. Inadequate content uniformity at the 0.5 mg dose.
3. Dissolution differences caused by excipient substitution.
4. Stability failures involving moisture, impurities, or packaging.
5. Labeling overlap with protected methods of use.
6. Inactive-ingredient or route-of-administration issues for a novel dosage form.

FDA's inactive-ingredient database can support excipient selection, but it does not replace product-specific safety, quality, and regulatory analysis.[6]

What Paragraph IV challenges and litigation affect Azilect?

Generic rasagiline products have reached the market, indicating that the core patent barriers did not prevent conventional generic competition. A Paragraph IV certification is a legal position that a listed patent is invalid, unenforceable, or not infringed. It is not an FDA finding on patent validity.[7]

For commercial planning, the relevant distinction is between:

• Legacy litigation involving the original Azilect patents.
• Current disputes involving generic manufacturers.
• Future litigation over a new ODT, oral film, fixed-dose combination, or manufacturing process.

A new formulation patent could create a separate litigation profile even though generic immediate-release tablets remain available. A company should therefore value formulation IP based on the product-specific claims and likely design-around options, not on the historic strength of Azilect's original patent estate.

What generic entry risks exist for an excipient-based rasagiline product?

Generic entry risk is high for a conventional tablet and moderate for a differentiated dosage form.

Conventional tablet

A standard tablet has:

• Low formulation complexity.
• Broad availability of pharmaceutical-grade excipients.
• Multiple potential manufacturing routes.
• Limited room for premium pricing.
• High risk of rapid price erosion.

Excipient substitution rarely creates a durable commercial moat unless it produces a measurable quality or clinical advantage.

ODT or oral film

An ODT or film may have stronger protection if the sponsor controls:

• A narrow composition range.
• A validated taste-masking system.
• A distinctive manufacturing process.
• A stability advantage.
• A clinically useful administration claim.
• A device or packaging system linked to product performance.

Design-around risk remains substantial because a competitor can select a different superdisintegrant, polymer, granulation process, or film-forming material.

How strong is the Azilect patent estate?

The legacy Azilect estate is weak as a barrier to conventional generic tablets because the product has long passed its original exclusivity period and generic rasagiline products are marketed.

A new lifecycle estate could be stronger if it combines:

• Composition claims.
• Process claims.
• Stability claims.
• Dosage-form claims.
• Method-of-use claims.
• Packaging or administration claims.

The strongest strategy is a layered portfolio with claims that cover both the commercial product and practical manufacturing alternatives. A single narrow excipient claim is unlikely to support meaningful exclusivity.

What licensing deals and partnerships could create value?

Commercial opportunities may arise through licensing rather than internal product development.

Potential counterparties include:

• Generic manufacturers with existing rasagiline API supply.
• Specialty pharmaceutical companies focused on Parkinson's disease.
• Contract development and manufacturing organizations with ODT or oral-film platforms.
• Excipient suppliers seeking a lead application for a co-processed excipient.
• Regional distributors with access to markets where rasagiline remains underpenetrated.

The most credible licensing package would include a validated formulation, scalable manufacturing process, freedom-to-operate analysis, stability data, and a regulatory pathway. A formulation concept without comparative performance data would have limited licensing value.

What manufacturing and geographic IP barriers apply?

Rasagiline excipient products face fewer manufacturing barriers than complex biologics or controlled-release systems. The principal barriers are operational:

• API supply and impurity control.
• Low-dose blend uniformity.
• Cleaning validation.
• Tablet weight and hardness control.
• Dissolution reproducibility.
• Moisture-protective packaging.
• Scale-up from laboratory to commercial equipment.

Geographic protection can be pursued through national composition, process, and dosage-form patents. Regulatory exclusivity also varies by jurisdiction. A formulation patent filed in the United States may not provide protection in Europe, Japan, China, or emerging markets unless corresponding applications are pursued and granted.

For global commercialization, excipient selection should account for regional acceptability, compendial status, supplier qualification, and local manufacturing conditions. A formulation dependent on a single proprietary excipient can create supply and licensing risk.

What is the revenue exposure and commercial outlook?

The immediate-release rasagiline market is exposed to generic price competition. Revenue potential is therefore more credible in differentiated products than in another standard tablet.

Strategy	Development complexity	Pricing potential	Competitive risk
Standard 0.5 mg tablet	Low	Low	High
Standard 1 mg tablet	Low	Low	High
ODT	Moderate	Moderate	Moderate
Oral film	Moderate to high	Moderate	Moderate
Fixed-dose combination	High	Higher if clinically useful	Moderate
Novel modified-release product	High	Potentially high	High regulatory risk
Regional private-label supply	Low to moderate	Low to moderate	High

A differentiated product should target a defined problem, such as dysphagia, adherence, dose flexibility, or administration in institutional settings. Excipients should be selected to support that product claim and manufacturing economics.

Key Takeaways

• Azilect is an immediate-release rasagiline mesylate tablet containing a conventional excipient system.
• The core tablet market is generic and offers limited premium opportunity.
• The most credible excipient-led opportunities are ODTs, oral films, taste-masked products, and fixed-dose combinations.
• Low-dose content uniformity is a central technical issue, particularly for the 0.5 mg strength.
• A standard excipient substitution is unlikely to create strong patent protection.
• Stronger lifecycle protection would combine composition, process, stability, dosage-form, and method-of-use claims.
• FDA Orange Book and ANDA strategy must be assessed against current listings, approved generics, and the proposed product label.
• Regional licensing and CDMO partnerships may reduce development cost and accelerate commercialization.
• Commercial value depends on solving a patient or manufacturing problem rather than changing the filler system alone.

FAQs

Can mannitol be replaced in a generic rasagiline tablet?

Yes. A generic applicant may use a different inactive-ingredient system if the product meets applicable quality, safety, stability, dissolution, and bioequivalence requirements.

Is rasagiline suitable for an orally disintegrating tablet?

Yes. Its low dose and existing use as an oral tablet make ODT development technically plausible, but taste, content uniformity, stability, and bioequivalence require product-specific validation.

Can an excipient combination receive a patent for rasagiline?

Yes, if the claimed combination has sufficient novelty and nonobviousness and is linked to a defined technical benefit. Conventional filler substitutions generally provide weaker patent positions.

Does Azilect still have meaningful patent protection against generic tablets?

The legacy product no longer provides a strong barrier to conventional generic rasagiline tablets. New dosage forms or combinations would require separate product-specific intellectual-property analysis.

Which excipient strategy has the highest commercial potential for rasagiline?

An adherence-focused ODT or taste-masked dosage form has the clearest excipient-led opportunity, particularly if it improves administration for Parkinson's patients with swallowing or dexterity limitations.

References

1. U.S. Food and Drug Administration. (2006). Azilect (rasagiline mesylate) prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Azilect, rasagiline mesylate tablet.
3. U.S. Food and Drug Administration. (2006). Zelapar (selegiline hydrochloride) prescribing information.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Rasagiline and Azilect approval records.
6. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
7. U.S. Food and Drug Administration. (2015). Approved drug products with therapeutic equivalence evaluations: Guidance on patent certifications and Paragraph IV submissions.